Renal end points in clinical trials of kidney disease по Weldegiorgis, M, De Zeeuw, D, Heerspink, HJL

Is chronic dialysis the right hard renal end point to evaluate renoprotective drug effects? по Weldegiorgis, M, de Zeeuw, D, Dwyer, J, Mol, P, Heerspink, H

Longitudinal estimated GFR trajectories in patients with and without type 2 diabetes and nephropathy по Weldegiorgis, M, de Zeeuw, D, Li, L, Parving, H, Hou, F, Remuzzi, G, Greene, T, Heerspink, H

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) - A randomized placebo-controlled trial по Neal, B, Perkovic, V, De Zeeuw, D, Mahaffey, K, Fulcher, G, Stein, P, Desai, M, Shaw, W, Jiang, J, Vercruysse, F, Meininger, G, Matthews, D

Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy plus /- oral agents in type 2 diabetes по Matthews, DR, Fulcher, G, Perkovic, V, de Zeeuw, D, Mahaffey, K, Rosenstock, J, Davies, M, Capuano, G, Desai, M, Shaw, W, Vercruysse, F, Meininger, G, Neal, B

Effects of lowering LDL cholesterol on progression of kidney disease. по Haynes, R, Lewis, D, Emberson, J, Reith, C, Agodoa, L, Cass, A, Craig, J, de Zeeuw, D, Feldt-Rasmussen, B, Fellström, B, Levin, A, Wheeler, D, Walker, R, Herrington, W, Baigent, C, Landray, M